IP Library Granted Patent US 9,174,021
Granted Patent B2
US 9,174,021 · App. 13/696,531 · Granted Nov 3, 2015

Catheter allowing variable dosing of an active agent

Inventors: Anthony Looper (Lake Zurich, IL); Griffin Strole (Chicago, IL)
Assignee: CAREFUSION 2200, INC.
A61M25/01A61M25/00A61M5/16877A61M25/007A61M2025/0008A61M2025/0293
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,174,021
App. No.
13/696,531
Granted
Nov 3, 2015
Kind
B2
Abstract

A drug eluting catheter includes an active agent, such as a drug or chemical substance, which is integrated with the catheter and allows variable dosing of the agent for elution to the patient's body. The catheter includes a dosing region and graduated markings or is associated with a measurement device that includes graduated markings that correspond to a range of dose of the active agent associated with the catheter. By removing or masking an undesired dosing region prior to administration, a user may vary the dosage to suit a patient's needs.

Claims (38)

1. A catheter system comprising:

a catheter comprising a dosing region; and

an active agent coated or embedded at the dosing region; and

a measurement device having graduated markings, wherein the graduated markings are indicative of a dosage of the active agent.

2. The catheter system of claim 1 , wherein the graduated markings are selected from the group consisting of lines, dots, alphanumeric characters, symbols, and fenestrations.

3. The catheter system of claim 1 , wherein the graduated markings include one or more colors.

4. A catheter comprising:

a dosing region;

an active agent coated or embedded at the dosing region; and

graduated markings disposed at the dosing region, wherein the graduated markings are indicative of a dosage of the active agent.

5. A method of administering an agent to a patient comprising:

providing a catheter comprising:

a dosing region; and

an agent coated or embedded at the dosing region;

providing a measurement device comprising graduated markings, wherein the graduated markings are indicative of a dosage of the agent; and

removing or masking a portion of the dosing region corresponding to a specific dosage of the agent.

6. A method of varying a dosage of an active agent comprising:

providing a catheter comprising:

a dosing region; and

an agent coated or embedded at the dosing region;

providing a measurement device comprising graduated markings, wherein each of the graduated markings is indicative of a different dosage of the active agent; and

removing or masking a portion of the dosing region corresponding to a specific dosage of the active agent.

7. A method of administering an agent to a patient comprising:

providing a catheter comprising:

a dosing region;

an agent coated or embedded at the dosing region; and

graduated markings disposed at the dosing region, wherein each of the graduated markings is indicative of a different dosage of the active agent; and

removing Or masking a portion of the dosing region corresponding to a specific dosage of the active agent.

8. A method of varying a dosage of an agent comprising:

providing a catheter comprising:

a dosing region;

an agent coated or embedded at the dosing region; and

graduated markings disposed at the dosing region, wherein each of the graduated markings is indicative of an incremental dosage of the active agent; and

removing or masking a portion of the dosing region corresponding to a dosage of the active agent required for treating a patient having a particular weight.

9. The catheter system of claim 1 , wherein the active agent is a sclerosing agent.

10. The catheter system of claim 9 , wherein the sclerosing agent is selected from a group consisting of talc, tetracycline, doxycycline, minocycline, doxorubicin, providone iodine, bleomycin, TGFβ and silver nitrate.

11. The catheter system of claim 5 , wherein the active agent is a sclerosing agent.

12. The catheter system of claim 11 , wherein the sclerosing agent is selected from a group consisting of talc, tetracycline, doxycycline, minocycline, doxorubicin, providone iodine, bleomycin, TGFβ and silver nitrate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2020
From: TREMBLAY, ALAIN
To: UTI LIMITED PARTNERSHIP
Reel/Frame 053669/0858 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2013
From: LOOPER, ANTHONY; STROLE, GRIFFIN
To: CAREFUSION 2200, INC.
Reel/Frame 030609/0632 →
Continuity (2)
Provisional Application 61332563 · May 7, 2010
Related Publication 20130281971A1 · Oct 24, 2013